These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 17693902

  • 1. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.
    Hemelaar M, Kenemans P, Hack CE, Klipping C, van der Mooren MJ.
    Menopause; 2008; 15(2):248-55. PubMed ID: 17693902
    [Abstract] [Full Text] [Related]

  • 2. Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women.
    Hemelaar M, Rosing J, Kenemans P, Thomassen MC, Braat DD, van der Mooren MJ.
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1660-6. PubMed ID: 16645152
    [Abstract] [Full Text] [Related]

  • 3. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B, Guzic-Salobir B, Sebestjen M, Keber I.
    Menopause; 2006 Jul; 13(4):643-50. PubMed ID: 16837886
    [Abstract] [Full Text] [Related]

  • 4. Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study.
    Davis SR, Stuckey BG, Norman RJ, Papalia MA, Drillich A, Bell RJ.
    Menopause; 2008 Jul; 15(6):1065-9. PubMed ID: 18806686
    [Abstract] [Full Text] [Related]

  • 5. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, Virkamäki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Järvinen H.
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [Abstract] [Full Text] [Related]

  • 6. Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women.
    Hemelaar M, Kenemans P, de Bie L, van de Weijer PH, van der Mooren MJ.
    Fertil Steril; 2006 Apr; 85(4):979-88. PubMed ID: 16580384
    [Abstract] [Full Text] [Related]

  • 7. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate.
    Junge W, El-Samalouti V, Gerlinger C, Schaefers M.
    Eur J Obstet Gynecol Reprod Biol; 2009 Dec; 147(2):195-200. PubMed ID: 19879683
    [Abstract] [Full Text] [Related]

  • 8. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women.
    Basurto L, Saucedo R, Zárate A, Martínez C, Gaminio E, Reyes E, Hernandez M.
    Gynecol Obstet Invest; 2006 Dec; 61(2):61-4. PubMed ID: 16192735
    [Abstract] [Full Text] [Related]

  • 9. No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women.
    Hemelaar M, Kenemans P, Schalkwijk CG, Braat DD, van der Mooren MJ.
    Hum Reprod; 2006 Jun; 21(6):1635-42. PubMed ID: 16501036
    [Abstract] [Full Text] [Related]

  • 10. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
    Post MS, Christella M, Thomassen LG, van der Mooren MJ, van Baal WM, Rosing J, Kenemans P, Stehouwer CD.
    Arterioscler Thromb Vasc Biol; 2003 Jun 01; 23(6):1116-21. PubMed ID: 12730085
    [Abstract] [Full Text] [Related]

  • 11. [Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens].
    Winkler UH, Krämer R, Kwee B, Schindler AE.
    Zentralbl Gynakol; 1995 Jun 01; 117(10):540-8. PubMed ID: 7491837
    [Abstract] [Full Text] [Related]

  • 12. Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17beta-estradiol and norethisterone when compared with an orally administered 17beta-estradiol norethisterone regimen.
    Rozenberg S, Pornel B, Koninckx PR, Palacios S, Christiansen C.
    Hum Reprod; 2009 Jul 01; 24(7):1739-47. PubMed ID: 19351658
    [Abstract] [Full Text] [Related]

  • 13. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC, Christodoulakos GE, Lambrinoudaki IV, Dalamanga A, Alexandrou AP, Bramis J, Bastounis E, Creatsas GC.
    Climacteric; 2007 Oct 01; 10(5):400-7. PubMed ID: 17852143
    [Abstract] [Full Text] [Related]

  • 14. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis.
    Teede HJ, McGrath BP, Smolich JJ, Malan E, Kotsopoulos D, Liang YL, Peverill RE.
    Arterioscler Thromb Vasc Biol; 2000 May 01; 20(5):1404-9. PubMed ID: 10807761
    [Abstract] [Full Text] [Related]

  • 15. Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women.
    Rachoń D, Suchecka-Rachoń K, Hak Ł, Myśliwska J.
    Menopause; 2006 May 01; 13(5):840-5. PubMed ID: 16894332
    [Abstract] [Full Text] [Related]

  • 16. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.
    Høibraaten E, Qvigstad E, Andersen TO, Mowinckel MC, Sandset PM.
    Thromb Haemost; 2001 May 01; 85(5):775-81. PubMed ID: 11372667
    [Abstract] [Full Text] [Related]

  • 17. Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause.
    Perrone G, Capri O, Galoppi P, Brunelli R, Bevilacqua E, Ceci F, Ciarla MV, Strom R.
    Gynecol Obstet Invest; 2009 May 01; 68(1):33-9. PubMed ID: 19349712
    [Abstract] [Full Text] [Related]

  • 18. The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
    Vogelvang TE, Mijatovic V, Kenemans P, Emeis JJ, Heijst JA, van der Mooren MJ.
    Am J Obstet Gynecol; 2005 Oct 01; 193(4):1384-94. PubMed ID: 16202731
    [Abstract] [Full Text] [Related]

  • 19. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.
    Eilertsen AL, Sandvik L, Mowinckel MC, Andersen TO, Qvigstad E, Sandset PM.
    Thromb Res; 2007 Oct 01; 120(3):371-9. PubMed ID: 17156824
    [Abstract] [Full Text] [Related]

  • 20. Lipids and clotting factors during low dose transdermal estradiol/norethisterone use.
    Brynhildsen J, Hammar M.
    Maturitas; 2005 Apr 11; 50(4):344-52. PubMed ID: 15780536
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.